Most Read Articles
09 Nov 2017
Treatment with fesoterodine shows efficacy in patients with nocturnal urgency secondary to overactive bladder syndrome and low nocturnal bladder capacity with a mismatch between nocturnal urine production and bladder capacity, reports a recent study.
Pearl Toh, 6 days ago
A study finds no evidence that using pharmaceutical aids alone for smoking cessation helps improve the chances of successful quitting despite promising results in previous randomized trials and routine prescription of such drugs to help quit smoking.
Roshini Claire Anthony, 05 Jan 2018

The addition of daratumumab to a bortezomib-melphalan-prednisone (VMP) regimen appears to improve progression-free survival (PFS) over VMP alone in individuals newly diagnosed with multiple myeloma who are ineligible for stem-cell transplantation, according to findings from the phase III ALCYONE* trial.

01 Jan 2012
A phase III, open-label, single-centre study presents the suitability of DTaP-IPV//PRP-T booster following primary vaccination with DTaP-IPV-Hep B-PRP-T vaccine.

Vancomycin with beta-lactam reduces SSI, ups AKI risk after cardiac surgery

30 Jul 2017

Combination prophylaxis with vancomycin and beta-lactam reduces surgical site infections (SSIs) in cardiac surgery patients better than either antimicrobial alone, a new retrospective cohort study shows. However, combination prophylaxis also increases the risk of postoperative acute kidney injury (AKI).

Participants who underwent hysterectomy (n=1,724), colorectal (n=7,337), vascular (n=7,405), orthopaedic joint replacement (n=33,848) and cardiac (n=19,787) procedures were recruited and further stratified according to prophylaxis received: vancomycin alone, beta-lactam alone or combination.

SSI, 7-day incidence of postoperative AKI and 90-day incidence of Clostridium difficile infection (CDI) were compared among the three groups.

SSI was detected in 0.95 percent (n=66) of cardiac surgery patients who received combination prophylaxis. In comparison, 1.48 percent (n=190) of patients receiving single-agent prophylaxis developed SSI.

The risk of postoperative SSI in cardiac surgery was lower after receiving combination prophylaxis (adjusted risk ratio [aRR], 0.61; 95 percent CI, 0.46 to 0.83). SSI risk was also lower with combination prophylaxis than with beta-lactam (aRR, 0.61; 0.45 to 0.83) or vancomycin (aRR, 0.65; 0.43 to 0.99) alone.

On the other hand, combination prophylaxis was not associated with significantly reduced SSI in the other types of surgeries.

Of the 12,508 participants who received combination prophylaxis, 0.72 percent (n=90) developed CDI. In comparison, 0.81 percent (n=486) of participants who received a single agent developed CDI. There was no association between CDI and combination prophylaxis (aRR, 1.01; 0.78 to 1.31).

Combination prophylaxis was associated with elevated risks of AKI 7 days after orthopaedic joint replacement (aRR, 1.12; 1.02 to 1.23) and vascular surgery (aRR, 1.25 1.04 to 1.50) compared with either beta-lactam or vancomycin alone.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
09 Nov 2017
Treatment with fesoterodine shows efficacy in patients with nocturnal urgency secondary to overactive bladder syndrome and low nocturnal bladder capacity with a mismatch between nocturnal urine production and bladder capacity, reports a recent study.
Pearl Toh, 6 days ago
A study finds no evidence that using pharmaceutical aids alone for smoking cessation helps improve the chances of successful quitting despite promising results in previous randomized trials and routine prescription of such drugs to help quit smoking.
Roshini Claire Anthony, 05 Jan 2018

The addition of daratumumab to a bortezomib-melphalan-prednisone (VMP) regimen appears to improve progression-free survival (PFS) over VMP alone in individuals newly diagnosed with multiple myeloma who are ineligible for stem-cell transplantation, according to findings from the phase III ALCYONE* trial.

01 Jan 2012
A phase III, open-label, single-centre study presents the suitability of DTaP-IPV//PRP-T booster following primary vaccination with DTaP-IPV-Hep B-PRP-T vaccine.